ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a Healthcare company (Biotechnology) with a market capitalization of $367M. The Maz Rating grades it against the other companies in its sector.
ARS Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.65, ARS Pharmaceuticals, Inc. trades at 3.0x sales. Over the last twelve months it generated about $123M of revenue and a net loss of $205M. It runs a gross margin of 73.4%, an operating margin of -161.5% and a net margin of -163.6%. It shows return on equity of -453.9%, return on invested capital of -105.7% and a free cash flow yield of -49.9%. On the balance sheet: a debt-to-equity ratio of -16.48 and a current ratio of 3.25. Over the past 52 weeks the share price ranged from $2.44 to $13.15, with a beta of 0.88.
ARS Pharmaceuticals, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 4 Buy and 6 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.